Chromatin immunoprecipitation (ChIP) assays revealed the significantly enriched binding of ATF4 to the GDF15 promoter in BMN673-treated ATM-deficient CRC cells (Fig. 5k). This evidence concerns the gene ATM and colorectal carcinoma.